

## Disclosures

### Personal Commercial (0)

No disclosures on record

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (7)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
ACC NCDR Science and Quality Committee Chair	Other - ACC Committee	None (\$0)	Other
AHA, Board of Directors, Western Affiliate (ended in 2018 or 2019)	Officer, Director, Trustee, or other Fiduciary Role	None (\$0)	General Cardiology
American Stroke Association, Cryptogenic Stroke Initiative Advisory Committee	Other	None (\$0)	
Catheterization and Cardiovascular Intervention	Other - Deputy Editor	Significant (>= \$5,000)	Invasive CV Angio and Interventions
FDA Circulatory Devices Panel Chair (July 1, 2022- † none	Other - Chair of the Circulatory Devices Panel	Modest (< \$5,000)	
SCAI DEI Committee Chair, Government Relations Co-chair Ended May 2024	Other - Committee Chair	None (\$0)	Invasive CV Angio and Interventions
SCAI: Board of Trustees and Vice President 2025 to May 2026	Officer, Director, Trustee, or other Fiduciary Role	None (\$0)	Invasive CV Angio and Interventions

### Clinical Trial Enroller (1)

Trial Name	Trial Sponsor	Trial Funding Source
Ischemia Trial	National Institutes of Health	

### Institutional Financial Decision-Making Role (1)

Funding Source	Institutional Compensation Level
Chief of Cardiology and Director of Knight CV Institute, OHSU	Significant (>= \$5,000)

### Expert Witness Testimony (3)

Year	Case Title	Represented	Description	Compensation
<i>Self</i>				
2021	Cardiac Arrest	Defendant	Patient experienced cardiac arrest after lidocaine injection and expired despite CPR/hospitalization due to anoxic brain injury	None (\$0)
2011	Coronary artery disease review	Defendant	review of documents for defendant	Modest (< \$5,000)
2010	Sudden death/coronary artery disease.	Defendant	Patient with stable angina who experienced sudden death on aspirin therapy prior to noninvasive risk stratification.	Modest (< \$5,000)

† Commercial Funding Source | ‡ Trial Name

## Agreement

**Certified Education Attestation** | Signed on 9/22/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

**Confidentiality, Disclosure and Assignment Agreement** | Signed on 9/22/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

**Embargo** | Signed on 9/22/2025

## **ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.